G12.0 Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]

Name of the Condition

• Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]

Summary

Infantile spinal muscular atrophy, type I (Werdnig-Hoffman disease) is a severe, inherited neuromuscular disorder characterized by progressive muscle weakness and atrophy due to the loss of motor neurons in the spinal cord. It is the most common and severe form of spinal muscular atrophy, typically presenting in infancy with profound hypotonia and respiratory compromise.

Causes

This condition is caused by mutations in the SMN1 gene, which is essential for the survival of motor neurons. Inherited in an autosomal recessive pattern, the disease results from a deficiency of the survival motor neuron (SMN) protein, critical for motor neuron function and maintenance.

Risk Factors

• Genetic inheritance: Carriers of SMN1 gene mutations have a 25% chance of passing the condition to offspring.
• Family history of spinal muscular atrophy or related neuromuscular disorders.
• Ethnic background: Higher prevalence in certain populations, such as individuals of European ancestry.

Symptoms

• Profound hypotonia (floppiness) and weakness, especially in the limbs and trunk.
• Difficulty with motor milestones, such as head control or sitting.
• Respiratory distress due to weakened respiratory muscles.
• Feeding difficulties and poor weight gain.
• Absent deep tendon reflexes.
• Fasciculations (muscle twitches) may be observed.

Diagnosis

Diagnosis involves clinical evaluation of hypotonia and motor delays, followed by genetic testing to confirm SMN1 gene mutations. Electromyography (EMG) and nerve conduction studies may assess motor neuron function, while muscle biopsy can rule out other neuromuscular disorders.

Treatment Options

• Supportive care: Respiratory support (e.g., ventilation) and nutritional management.
• Physical therapy to maintain joint mobility and prevent contractures.
• Medications: Nusinersen (Spinraza) or onasemnogene abeparvovec (Zolgensma) may be used to increase SMN protein levels, where appropriate.
• Multidisciplinary care involving neurologists, pulmonologists, and dietitians.

Prognosis and Follow-Up

Prognosis is poor, with most infants requiring respiratory support and many not surviving beyond the first two years. Regular follow-up with specialists is essential to manage respiratory and nutritional needs, and to adjust care plans as the disease progresses.

Complications

• Respiratory failure due to weakened respiratory muscles.
• Feeding difficulties leading to malnutrition or aspiration.
• Joint contractures and skeletal deformities from prolonged immobility.
• Increased susceptibility to respiratory infections.

Lifestyle & Prevention

• Genetic counseling for families with a history of the condition.
• Prenatal testing (e.g., chorionic villus sampling or amniocentesis) for at-risk pregnancies.
• Early intervention with physical and respiratory therapies to optimize function.

When to Seek Professional Help

Seek immediate medical attention if an infant shows signs of severe hypotonia, respiratory distress, or feeding difficulties. Early diagnosis and intervention are critical for managing symptoms and improving outcomes.

Tips for Medical Coders

• Use G12.0 for infantile spinal muscular atrophy, type I (Werdnig-Hoffman disease).
• Document the presence of SMN1 gene mutations or genetic testing results to support the diagnosis.
• Include details of respiratory support, feeding interventions, or specific therapies (e.g., nusinersen) in the medical record for accurate coding.
• Ensure the code aligns with clinical documentation of the condition’s severity and associated complications.